Laboratory of Immunology, Section for Experimental Animal Models, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
FASEB J. 2020 Nov;34(11):15531-15546. doi: 10.1096/fj.202000162R. Epub 2020 Sep 30.
SCFAs are primarily produced in the colon by bacterial fermentation of nondigestible carbohydrates. Besides providing energy, SCFAs can suppress development of colon cancer. The mechanism, however, remains elusive. Here, we demonstrate that the SCFA propionate upregulates surface expression of the immune stimulatory NKG2D ligands, MICA/B by imposing metabolic changes in dividing cells. Propionate-mediated MICA/B expression did not rely on GPR41/GPR43 receptors but depended on functional mitochondria. By siRNA-directed knockdown, we could further link phosphoenolpyruvate carboxykinase (PEPCK), the rate-limiting enzyme in gluconeogenesis to propionate regulation of MICA/B expression. Moreover, knockdown of Rictor and specific mTOR inhibitors implicated mTORC2 activity with metabolic changes that control MICA/B expression. SCFAs are precursors to short-chain acyl-CoAs that are used for histone acylation thereby linking the metabolic state to chromatin structure and gene expression. Propionate increased the overall acetylation and propionylation and inhibition of lysine acetyltransferases (KATs) that are responsible for adding acyl-CoAs to histones reduced propionate-mediated MICA/B expression, suggesting that propionate-induced acylation increases MICA/B expression. Notably, propionate upregulated MICA/B surface expression on colon cancer cells in an acylation-dependent manner; however, the impact of mitochondrial metabolism on MICA/B expression was different in colon cancer cells compared with Jurkat cells, suggesting that continuous exposure to propionate in the colon may provide an enhanced capacity to metabolize propionate. Together, our findings support that propionate causes metabolic changes resulting in NKG2D ligand surface expression, which holds potential as an immune activating anticancer therapy.
短链脂肪酸(SCFAs)主要通过细菌对不可消化碳水化合物的发酵在结肠中产生。除了提供能量外,SCFAs 还可以抑制结肠癌的发展。然而,其机制尚不清楚。在这里,我们证明 SCFA 丙酸盐通过对分裂细胞施加代谢变化来上调免疫刺激 NKG2D 配体 MICA/B 的表面表达。丙酸盐介导的 MICA/B 表达不依赖于 GPR41/GPR43 受体,而是依赖于功能线粒体。通过 siRNA 指导的敲低,我们可以进一步将磷酸烯醇丙酮酸羧激酶(PEPCK),即糖异生的限速酶与丙酸盐调节 MICA/B 表达联系起来。此外,敲低 Rictor 和特定的 mTOR 抑制剂表明 mTORC2 活性与控制 MICA/B 表达的代谢变化有关。SCFAs 是短链酰基辅酶 A(acyl-CoA)的前体,用于组蛋白酰基化,从而将代谢状态与染色质结构和基因表达联系起来。丙酸盐增加了整体乙酰化和丙酰化,并且抑制负责将酰基辅酶 A 添加到组蛋白的赖氨酸乙酰转移酶(KATs)减少了丙酸盐介导的 MICA/B 表达,这表明丙酸盐诱导的酰基化增加了 MICA/B 的表达。值得注意的是,丙酸盐以依赖于酰基化的方式在上皮癌细胞表面上调 MICA/B 的表达;然而,与 Jurkat 细胞相比,线粒体代谢对 MICA/B 表达的影响在结肠癌细胞中不同,这表明结肠中持续暴露于丙酸盐可能提供了增强的代谢丙酸盐的能力。总之,我们的研究结果支持丙酸盐引起代谢变化,导致 NKG2D 配体表面表达,这可能作为一种免疫激活的抗癌治疗方法。